Developer docs
API playgroundTry for free, no card

Search company profiles

Third Pole

Full company profile

uuid0000zgw

Namestring
Third Pole
Legal namestring
Third Pole, Inc.
Websiteurl
pole3.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nitric oxide therapy, inhaled nitric oxide, cardiopulmonary medical devices, respiratory care devices, portable therapeutic devices
Industry4 codes
PRIMARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAK
Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAIAE
Wearable Injectors & On-Body Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMAEACAF
Medical & Healthcare Gases
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Inhaled Nitric Oxide Therapy Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1eNOcare™ Hospital Device Sales
TypeHardware Sales
Description

Sale or licensing of the eNOcare™ portable in-hospital nitric oxide delivery device into the existing $600M iNO hospital market. The device targets large hospitals and developed markets where iNO is already established for treating newborn respiratory failure and post-cardiac surgery patients.

pole3.com
2eNOfit™ Wearable/Outpatient Device Sales
TypeHardware Sales
Description

Sale of the miniaturized wearable eNOfit™ device targeting the outpatient/home market for patients with severe COPD, ILD, and pulmonary hypertension. The device targets 1.2M–1.5M patients struggling with chronic lung diseases, with a commercial opportunity estimated to exceed $12B annually.

pole3.com
3NO Generation Technology Licensing
TypeLicensing Royalties
Description

The broadly patented NO generation technology may be licensed to other companies. The company has expressed openness to partnerships for creating, developing, and commercializing cardio-pulmonary products that expand current markets and create new markets.

pole3.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1No publicly disclosed pricing tiers available for Third Pole's eNOfit™ or eNOcare™ devices.
ModelOtherBilling cadencePay-as-you-go
Notes

Both eNOfit™ and eNOcare™ are investigational products not yet cleared or approved in the United States. Pricing information is not yet publicly available. The existing iNO market costs approximately $2,800 per day for compressed gas-based delivery systems.

pole3.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1eNOfit
Description

Miniaturized wearable device for home and travel use, providing portable inhaled nitric oxide therapy for patients with pulmonary hypertension associated with ILD and COPD.

pole3.com
+1 more record
Core offering1 text field

Third Pole develops tankless, on-demand inhaled nitric oxide (iNO) generation and delivery devices for hospital and ambulatory use. Its two investigational platforms—eNOcare™ (a portable in-hospital device) and eNOfit™ (a miniaturized, ~2-pound wearable device)—produce therapeutic nitric oxide from ambient air and electricity using patented pulsed electrical discharge technology, eliminating the need for compressed gas cylinders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Market opportunity for eNOfit™ estimated to exceed $12B annually
+6 more records
Product overview1 text field

Third Pole Therapeutics offers two distinct medical device platforms for inhaled nitric oxide (iNO) therapy: eNOfit™ (a miniaturized, two-pound wearable device for home and travel use) and eNOcare™ (a lightweight portable in-hospital device). Both platforms use proprietary technology that generates NO on-demand by combining electricity and ambient air, creating a 'make it and take it' therapy that eliminates the need for compressed gas tanks. The platforms are designed to serve different care settings—the eNOfit™ for ambulatory/outpatient use and eNOcare™ for hospital use—while sharing the same core tankless NO generation technology. Both products are investigational and not currently FDA cleared or approved.

Product and service2 records
1eNOfit™
CategoryWearable Respiratory Therapy Device
Description

A miniaturized, portable inhaled nitric oxide generator and delivery system designed for ambulatory/outpatient use. The approximately two-pound wearable device generates NO on-demand from electricity and ambient air, providing treatment for patients with pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD) and COPD. Currently investigational, not yet FDA cleared or approved.

2eNOcare™
CategoryIn-Hospital Respiratory Therapy Device
Description

A lightweight portable in-hospital device for delivering inhaled nitric oxide (iNO) therapy. Designed to increase access and affordability of nitric oxide treatment in hospital settings, generating NO on-demand from electricity and ambient air. Received FDA breakthrough designation; targeted for FDA submission as of 2022-2023. Investigational, not yet FDA cleared or approved.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1U.S. Patent and Trademark Office (USPTO)
Strategic tierCoreTypeOthersAnnounced on2019-08-21
Description

The USPTO issued new U.S. patents covering Third Pole's innovative general and portable inhaled nitric oxide delivery systems, providing the company with broad intellectual property protection for its tankless iNO technology.

pole3.com
2Actelion Pharmaceuticals Ltd (Janssen Pharmaceutical Company of Johnson & Johnson)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-03-26
Description

Third Pole entered into a strategic collaboration with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson, to advance inhaled nitric oxide therapy. This collaboration was announced March 26, 2019. Actelion is a leading pharmaceutical company in pulmonary hypertension, making this a strategically aligned partnership for market expansion.

pole3.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Erin McKenna, Board Observer representing Partners/MGH, is a leader in the Boston Biomedical Innovation Center, a life sciences accelerator funded by the NIH. This connection facilitates NIH-funded innovation support for Third Pole.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-05-04
Description

Third Pole won the Johnson & Johnson Innovation JLABS @ M2D2 QuickFire Challenge in May 2017, receiving recognition and support from J&J's innovation ecosystem for its lighter nitric oxide system.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Third Pole's core technology is based on innovations developed by founder Warren Zapol at Harvard's Massachusetts General Hospital. The company maintains ongoing R&D and clinical collaborations with MGH, with Erin McKenna representing Partners/MGH on Third Pole's board. Clinical studies for eNOfit™ are conducted with MGH-affiliated investigators.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Aerogen specializes in aerosol drug delivery systems for ventilated and spontaneously breathing patients in the hospital setting. It is an emerging player in inhaled respiratory drug/device delivery, comparable in technology category to Third Pole's hospital iNO delivery device.

TypeBroad incumbent
Description

ResMed is a global leader in respiratory care devices including portable oxygen and ventilation equipment for COPD and chronic lung disease patients. It represents a broader incumbent in portable/home respiratory therapy adjacent to Third Pole's eNOfit™ market.

TypeBroad incumbent
Description

Philips Respironics manufactures hospital and home respiratory care equipment, including ventilators and oxygen concentrators. It is a broad incumbent in the respiratory device space where Third Pole's eNOcare™ and eNOfit™ compete for hospital and home-care share.

TypeBroad incumbent
Description

United Therapeutics markets Tyvaso® (inhaled treprostinil) and other therapies for pulmonary arterial hypertension and PH-ILD. It is a broad incumbent in the same therapeutic indication space Third Pole's eNOfit™ targets, representing an established alternative therapy.

TypeEmerging player
Description

Pulmonx develops interventional treatments for severe COPD and emphysema (Zephyr® valves). It is an emerging player in the same severe-COPD patient population Third Pole targets with eNOfit™, representing a different therapeutic modality for overlapping indications.

TypeBroad incumbent
Description

Inogen is a leader in portable oxygen concentrators for chronic respiratory disease patients (COPD, ILD) in the home/ambulatory setting. It addresses the same patient population Third Pole targets with eNOfit™, but with oxygen rather than nitric oxide, and represents a relevant portable respiratory device comparable.

TypeBroad incumbent
Description

Mallinckrodt owns INOmax, the dominant inhaled nitric oxide therapy (>USD 400M annual revenue before acquisition for $2.3B). It is the entrenched incumbent in the hospital iNO market that Third Pole must displace or differentiate against.

TypeDirect peer
Description

Vero Biotech has developed and received FDA approval for Genosyl®, a tankless inhaled nitric oxide delivery system. It is the most direct competitive threat to Third Pole, addressing the same hospital iNO market with a similar on-demand generation approach.

TypeDirect peer
Description

Beyond Air develops nitric oxide-based therapies for respiratory and infectious diseases, including LungFit® systems. It overlaps with Third Pole on inhaled NO generation technology and pulmonary indications, though it has focused more on hospital-based anti-infective applications.

10Bellerophon Therapeutics
TypeEmerging player
Description

Bellerophon develops INOpulse®, a proprietary inhaled nitric oxide delivery system targeting pulmonary hypertension and cardiopulmonary diseases. It targets overlapping patient populations (PH-ILD, PH-COPD) with Third Pole's eNOfit™ and is a relevant emerging competitor in ambulatory iNO.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Third Pole

Inhaled Nitric Oxide Therapy Devicespole3.com

Third Pole firmographics

Firmographics
Name
Third Pole
Legal name
Third Pole, Inc.
Website
https://pole3.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Third Pole industry classification

Industry
Product category
Inhaled Nitric Oxide Therapy Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAK
Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAIAE
Wearable Injectors & On-Body Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMAEACAF
Medical & Healthcare Gases

Keywords

  • Nitric oxide therapy
  • Inhaled nitric oxide
  • Cardiopulmonary medical devices
  • Respiratory care devices
  • Portable therapeutic devices

Where Third Pole is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Third Pole business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. eNOcare™ Hospital Device Sales: Sale or licensing of the eNOcare™ portable in-hospital nitric oxide delivery device into the existing $600M iNO hospital market. The device targets large hospitals and developed markets where iNO is already established for treating newborn respiratory failure and post-cardiac surgery patients.
  2. eNOfit™ Wearable/Outpatient Device Sales: Sale of the miniaturized wearable eNOfit™ device targeting the outpatient/home market for patients with severe COPD, ILD, and pulmonary hypertension. The device targets 1.2M–1.5M patients struggling with chronic lung diseases, with a commercial opportunity estimated to exceed $12B annually.
  3. NO Generation Technology Licensing: The broadly patented NO generation technology may be licensed to other companies. The company has expressed openness to partnerships for creating, developing, and commercializing cardio-pulmonary products that expand current markets and create new markets.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo publicly disclosed pricing tiers available for Third Pole's eNOfit™ or eNOcare™ devices.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Third Pole product offering

Product offering

Core offering

Third Pole develops tankless, on-demand inhaled nitric oxide (iNO) generation and delivery devices for hospital and ambulatory use. Its two investigational platforms—eNOcare™ (a portable in-hospital device) and eNOfit™ (a miniaturized, ~2-pound wearable device)—produce therapeutic nitric oxide from ambient air and electricity using patented pulsed electrical discharge technology, eliminating the need for compressed gas cylinders.

Product overview

Third Pole Therapeutics offers two distinct medical device platforms for inhaled nitric oxide (iNO) therapy: eNOfit™ (a miniaturized, two-pound wearable device for home and travel use) and eNOcare™ (a lightweight portable in-hospital device). Both platforms use proprietary technology that generates NO on-demand by combining electricity and ambient air, creating a 'make it and take it' therapy that eliminates the need for compressed gas tanks. The platforms are designed to serve different care settings—the eNOfit™ for ambulatory/outpatient use and eNOcare™ for hospital use—while sharing the same core tankless NO generation technology. Both products are investigational and not currently FDA cleared or approved.

Differentiator

Problem solved

Functional benefit

Brands

  • eNOfit: Miniaturized wearable device for home and travel use, providing portable inhaled nitric oxide therapy for patients with pulmonary hypertension associated with ILD and COPD.
  • eNOcare

Products and services

  • eNOfit™ A miniaturized, portable inhaled nitric oxide generator and delivery system designed for ambulatory/outpatient use. The approximately two-pound wearable device generates NO on-demand from electricity and ambient air, providing treatment for patients with pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD) and COPD. Currently investigational, not yet FDA cleared or approved.
  • eNOcare™ A lightweight portable in-hospital device for delivering inhaled nitric oxide (iNO) therapy. Designed to increase access and affordability of nitric oxide treatment in hospital settings, generating NO on-demand from electricity and ambient air. Received FDA breakthrough designation; targeted for FDA submission as of 2022-2023. Investigational, not yet FDA cleared or approved.

Quantifiable outcome

  • Market opportunity for eNOfit™ estimated to exceed $12B annually
  • +6 more outcomes

Companies that use Third Pole

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Third Pole technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Third Pole partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • U.S. Patent and Trademark Office (USPTO)coreOthers · 21 August 2019The USPTO issued new U.S. patents covering Third Pole's innovative general and portable inhaled nitric oxide delivery systems, providing the company with broad intellectual property protection for its tankless iNO technology.
  • Actelion Pharmaceuticals Ltd (Janssen Pharmaceutical Company of Johnson & Johnson)coreStrategic or Co-development Partner · 26 March 2019Third Pole entered into a strategic collaboration with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson, to advance inhaled nitric oxide therapy. This collaboration was announced March 26, 2019. Actelion is a leading pharmaceutical company in pulmonary hypertension, making this a strategically aligned partnership for market expansion.
  • Boston Biomedical Innovation Center (B-BIC)minorStrategic or Co-development Partner · 1 January 2019Erin McKenna, Board Observer representing Partners/MGH, is a leader in the Boston Biomedical Innovation Center, a life sciences accelerator funded by the NIH. This connection facilitates NIH-funded innovation support for Third Pole.
  • Johnson & Johnson Innovation (JLABS @ M2D2)minorStrategic or Co-development Partner · 4 May 2017Third Pole won the Johnson & Johnson Innovation JLABS @ M2D2 QuickFire Challenge in May 2017, receiving recognition and support from J&J's innovation ecosystem for its lighter nitric oxide system.
  • Massachusetts General Hospital (MGH)coreStrategic or Co-development Partner · 1 January 2014Third Pole's core technology is based on innovations developed by founder Warren Zapol at Harvard's Massachusetts General Hospital. The company maintains ongoing R&D and clinical collaborations with MGH, with Erin McKenna representing Partners/MGH on Third Pole's board. Clinical studies for eNOfit™ are conducted with MGH-affiliated investigators.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Third Pole competitors and assessment

Company assessment

Emerging players

  • Aerogen: Aerogen specializes in aerosol drug delivery systems for ventilated and spontaneously breathing patients in the hospital setting. It is an emerging player in inhaled respiratory drug/device delivery, comparable in technology category to Third Pole's hospital iNO delivery device.
  • Pulmonx: Pulmonx develops interventional treatments for severe COPD and emphysema (Zephyr® valves). It is an emerging player in the same severe-COPD patient population Third Pole targets with eNOfit™, representing a different therapeutic modality for overlapping indications.
  • Bellerophon Therapeutics: Bellerophon develops INOpulse®, a proprietary inhaled nitric oxide delivery system targeting pulmonary hypertension and cardiopulmonary diseases. It targets overlapping patient populations (PH-ILD, PH-COPD) with Third Pole's eNOfit™ and is a relevant emerging competitor in ambulatory iNO.

Broad incumbents

  • ResMed: ResMed is a global leader in respiratory care devices including portable oxygen and ventilation equipment for COPD and chronic lung disease patients. It represents a broader incumbent in portable/home respiratory therapy adjacent to Third Pole's eNOfit™ market.
  • Philips Respironics: Philips Respironics manufactures hospital and home respiratory care equipment, including ventilators and oxygen concentrators. It is a broad incumbent in the respiratory device space where Third Pole's eNOcare™ and eNOfit™ compete for hospital and home-care share.
  • United Therapeutics: United Therapeutics markets Tyvaso® (inhaled treprostinil) and other therapies for pulmonary arterial hypertension and PH-ILD. It is a broad incumbent in the same therapeutic indication space Third Pole's eNOfit™ targets, representing an established alternative therapy.
  • Inogen: Inogen is a leader in portable oxygen concentrators for chronic respiratory disease patients (COPD, ILD) in the home/ambulatory setting. It addresses the same patient population Third Pole targets with eNOfit™, but with oxygen rather than nitric oxide, and represents a relevant portable respiratory device comparable.
  • Mallinckrodt Pharmaceuticals (INO Therapeutics): Mallinckrodt owns INOmax, the dominant inhaled nitric oxide therapy (>USD 400M annual revenue before acquisition for $2.3B). It is the entrenched incumbent in the hospital iNO market that Third Pole must displace or differentiate against.

Direct peers

  • Vero Biotech: Vero Biotech has developed and received FDA approval for Genosyl®, a tankless inhaled nitric oxide delivery system. It is the most direct competitive threat to Third Pole, addressing the same hospital iNO market with a similar on-demand generation approach.
  • Beyond Air: Beyond Air develops nitric oxide-based therapies for respiratory and infectious diseases, including LungFit® systems. It overlaps with Third Pole on inhaled NO generation technology and pulmonary indications, though it has focused more on hospital-based anti-infective applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Third Pole social profiles

Digital presence

Third Pole compliance and trust

Trust signal

Compliance1 record

Third Pole financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Third Pole leadership team

Management profile

Number of profiles

Profiles7 records

Third Pole funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Third Pole M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Third Pole

What does Third Pole do?

Third Pole develops tankless, on-demand inhaled nitric oxide (iNO) generation and delivery devices for hospital and ambulatory use. Its two investigational platforms—eNOcare™ (a portable in-hospital device) and eNOfit™ (a miniaturized, ~2-pound wearable device)—produce therapeutic nitric oxide from ambient air and electricity using patented pulsed electrical discharge technology, eliminating the need for compressed gas cylinders.

Is Third Pole a public or private company?

Third Pole is a private company. It is classified as venture growth investor backed and is currently operating.

When was Third Pole founded?

Third Pole was founded in 2014. It employs 11 to 50 people.

Where is Third Pole based?

Third Pole is headquartered in Waltham, United States, in the North America region.

How does Third Pole make money?

Three revenue lines are on record. eNOcare™ Hospital Device Sales are the primary driver. The others are eNOfit™ Wearable/Outpatient Device Sales and NO Generation Technology Licensing.

Who are Third Pole's main competitors?

Emerging players on record are Aerogen, Pulmonx and Bellerophon Therapeutics. Broad incumbents are ResMed, Philips Respironics, United Therapeutics, Inogen and Mallinckrodt Pharmaceuticals (INO Therapeutics). Direct peers are Vero Biotech and Beyond Air.

Does Third Pole have an API?

No public API is recorded for Third Pole.

What industry is Third Pole in?

Third Pole's product category is Inhaled Nitric Oxide Therapy Devices. Its primary akta.pro industry code is HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories), with a secondary code of HLAHAGAK, Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pole3Third Pole TherapeuticsThird Pole Therapeutics has successfully completed an early feasibility study of its portable inhaled nitric oxide delivery device, eNOfit. This achievement allows the company to proceed to larger clinical trials for treating pulmonary hypertension associated with interstitial lung disease.Pole3Third Pole TherapeuticsThird Pole Therapeutics successfully completed an early feasibility study of its portable inhaled nitric oxide device, eNOfit. This achievement allows the company to proceed with larger clinical trials for pulmonary hypertension associated with interstitial lung disease.Pole3Third Pole TherapeuticsThird Pole Therapeutics successfully completed an early feasibility study of its portable inhaled nitric oxide delivery device, eNOfit. This achievement allows the company to proceed to larger clinical trials for treating pulmonary hypertension associated with interstitial lung disease.PulmonaryhypertensionnewsThird Pole’s portable inhaled nitric oxide device clears early studyThird Pole Therapeutics announced the successful completion of an early feasibility study of its portable inhaled nitric oxide (iNO) delivery device, eNOfit, for pulmonary hypertension associated with interstitial lung disease, clearing the way for larger randomized placebo-controlled safety and efficacy studies expected to launch this year. The device electrically generates an unlimited supply of iNO directly from air, weighs two pounds, and is designed to enable mobile at-home and ambulatory treatment without compressed gas cylinders. Third Pole received a Johnson & Johnson Innovation award for the device in 2017 through the JLABS @ M2D2 program.BioSpaceThird Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery SystemThird Pole Therapeutics announced successful completion of an early feasibility study (EFS) for its eNOfit™ portable inhaled nitric oxide delivery system, conducted under an FDA Investigational Device Exemption, evaluating treatment for pulmonary hypertension associated with Interstitial Lung Disease. The study validated the safe and practical use of the device, enabling the company to advance into larger randomized placebo-controlled safety and efficacy trials. The milestone triggers final funding for Third Pole's Series B investment round, which includes a previously announced $32M strategic equity investment from one of the world's largest healthcare companies.GlobeNewswireThird Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery SystemThird Pole Therapeutics completed an early feasibility study of its eNOfit portable inhaled nitric oxide device for pulmonary hypertension. The study validated safe and practical use, enabling larger randomized placebo-controlled trials and triggering final funding of its Series B round.YahooThird Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery SystemThird Pole Therapeutics completed an early feasibility study of its eNOfit portable inhaled nitric oxide device for pulmonary hypertension. The study validated safe and practical use, enabling larger randomized trials and triggering final funding of its Series B round.Pole3Third Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery SystemThird Pole Therapeutics announced the successful completion of an early feasibility study for its eNOfit™ portable inhaled nitric oxide delivery system, conducted under an FDA Investigational Device Exemption, evaluating the device for treatment of pulmonary hypertension associated with Interstitial Lung Disease. The successful study completion enables the company to advance to larger randomized placebo-controlled safety and efficacy trials and has triggered the final funding of Third Pole's Series B investment round. The company also noted a prior $32M strategic equity investment from a major healthcare company to accelerate development of its tankless iNO platform.National Center for Biotechnology InformationElectrifying Invention Can Save Young Lives and Ease Chronic Lung ConditionsThird Pole Therapeutics, a Waltham, Massachusetts-based company founded by the late Dr. Warren Zapol and his son, has developed a portable device that generates therapeutic nitric oxide (NO) on-demand using electricity from ambient air, eliminating the need for compressed gas tanks used since FDA approval in 1999. The technology, based on mimicking how lightning produces NO in the atmosphere, could make iNO therapy more accessible and affordable for treating respiratory conditions in newborns and adults with chronic lung disorders. The company has received NIH funding through Small Business Innovation Research grants and is working toward completion of design verification testing and clinical evaluation.Medical Device NetworkThird Pole doses first patient in trial with nitric oxide delivery systemThird Pole Therapeutics has dosed the first patient in an early feasibility trial evaluating its portable inhaled nitric oxide delivery system eNOfit for patients with pulmonary hypertension accompanying interstitial lung disease. The device, operating under an FDA investigational device exemption, is being studied across multiple centers with results expected in Q1 2024 and enrollment of approximately five participants receiving doses at 2mg/h and 6mg/h. The company plans to use these findings to design a larger randomized placebo-controlled safety and efficacy study planned for 2024, building toward home and ambulatory use for the estimated millions of patients suffering from this condition.